Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer

Acta Oncologica

Volumn 47, Issue 3, 2008, Pages 337-346

  Sgouros, Joseph ^a   Maraveyas, Anthony ^a  

^a PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN C; OCTREOTIDE; OXALIPLATIN; PEMETREXED; TANOMASTAT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HEALTH STATUS; HEART INFARCTION; HUMAN; HYPOTHESIS; INFECTION; INTERNET; KIDNEY FAILURE; LUNG EMBOLISM; METASTASIS; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; INFECTION; KARNOFSKY PERFORMANCE STATUS; KIDNEY FAILURE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; THROMBOEMBOLISM; THROMBOPHILIA; TIME FACTORS;

EID: 40949158476     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701687267     Document Type: Review

References (45)

1. Cancer Research UK. UK pancreatic cancer mortality statistics (Assessed 14 April 2007 at http://info.cancer researchuk.org./cancerstats/types/pancreas/ mortality/).
2. Pancreatic cancer action network. Pancreatic cancer facts for 2007 (Assessed 11 April 2007, at http://pancan.org/About/pancreaticCancerStats.html).
3. Cardenes HR, Chiorean EG, DeWitt J, Schmidt M, Loehrer P. Locally advanced pancreatic cancer: Current therapeutic approach. Oncologist 2006;11:612-23.
4. Yeo CJ, Yeo TP, Hruban RH, Kern SE, Iacobuzio-Donahue CA, Maitra A, et al. Cancer of the pancreas. In: De Vita Jr VT, Hellman S, Rosenberg SA, editors. Cancer. Principles and practice of Oncology. th ed. Philadelphia: Lippincott Williams and Willkins; 2005. p. 945-86.
5. Agnieszka M, Hill M, Maraveyas A, Wasan H, Lofts F. Phase I/II study to investigate the use of gemcitabine in combination with raltitrexed in locally advanced or metastatic pancreatic adenocarcinoma. Internet J Oncol 2006;3.
6. Michael A, Hill M, Maraveyas A, Dalgleish A, Lofts F. 13-cis-retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer - report of a pilot phase II study. Clin Oncol (R Coll Radiol) 2007;19:150-3.
7. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997;15:2403-13.
8. Ducreux M, Rougier P, Pignon JP, Douillard JY, Seitz JF, Bugat R, et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002;13:1185-91.
9. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-10.
10. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vernenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-8.
11. Shapiro J, Marshall J, Karasek P, Fige A, Oettle H, Couture F, et al. G17DT +gemcitabine [Gem] versus placebo +Gem in untreated subjects with locally advanced, recurrent or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 2005;23(16S):4012.
12. Wright JA, Osterlee J, Fekete S, Lee Y, Young AH. A phase III trial of virulizin plus gemcitabine vs. gemcitabine alone in advanced pancreatic cancer: Results of subgroup analysis. J Clin Oncol 2006 Annual Meeting Proceedings 2006;24(18S):4116.
13. Burch PA, Block M, Schroeder G, Kugler JW, Sargent DJ, Braich TA, et al. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A north central cancer treatment group. Clin Cancer Res 2000;6:3486-92.
14. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 2001;19:3447-55.
15. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-fu) with PVI 5-fu plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002;14:3130-6.
16. rd. Phase III study of gemcitabine in combination with flurouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-5.
17. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JAC. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7.
18. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Fields A, Hagan K, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-302.
19. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey M, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
20. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005;16:1639-45.
21. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial. Lancet Oncol 2005;6:369-76.
22. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
23. Heinneman V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
24. Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, et al. A multicenter phase III study comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006;95:587-92.
25. Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006;24:4441-7.
26. Chevreton P, Friess H, Andras C, Salek T, Geddes C, Bodoky G, et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy naive patients with advanced pancreatic cancer (APC). J Clin Oncol, 2004 ASCO Annual Meeting Proc;22(14S):4005.
27. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, et al. Erlotinib plus gemcitabine compared to gemcitabine alone, in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol, 2005 ASCO Annual Meeting Proc;23(16S):1.
28. Riess H, Helm A, Niedergethmann M, Schmidt-Wolf I, Moik M, Hammer C, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proc;23(16S):4009.
29. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol, 2005 ASCO Annual Meeting Proc;23(16S):4010.
30. Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[FDR]) versus gemcitabine-oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol, 2006 ASCO Annual Meeting Proc;24(18S):LBA4004.
31. Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM, et al. Adjuvant therapy in pancreatic cancer: Historical and current perspectives. Ann Oncol 2003;14:675-92.
32. Woodruff KH, Castro TJR, Quivey JM, Saunders WM, Chen GT, Lyman JT, et al. Post-mortem examination of 22 pancreatic carcinoma patients treated with helium ion irradiation. Cancer 1984;53:420-5.
33. Park K, Kim M, Park S, Lee KJ. Nervous system involvement by pancreatic cancer. Neuro-Oncol 2003;63:313-6.
34. Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. Dig Surg 2005;22:401-14.
35. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001;358:1576-85.
36. Sproul EE. Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938;34:566-85.
37. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004;5:655-63.
38. Ögren M, Bergqvist D, Wahlanden K, Eriksson H, Sternby NH. Trousseau's syndrome-what is the evidence? A population-based autopsy study. Thromb Haemost 2006;95:541-5.
39. Blom JW, Osanto S, Rosendall FR. High risk of venous thrombosis in patients with pancreatic cancer: A cohort study of 202 patients. Eur J Cancer 2006;42:410-4.
40. Nakchbandi W, Muller H, Singer MV, Lohr M, Nakchandi IA. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand J Gastroenterol 2006;41:1095-104.
41. Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007;95:507-12.
42. Maraveyas A, Holmes M, Lofts F, Garadi KK, Gardiner E, Sgouros J Chemoanticoagulation versus chemotherapy in advanced pancreatic cancer (APC): Results of the interim analysis of the FRAGEM trial. J Clin Oncol 2007ASCO Annual Meeting Proceedings 2007;25(18S):4583.
43. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5.
44. Hillen HF. Thrombosis in cancer patients. Ann Oncol 2000;11(Suppl3):273- 6.
45. Storto ML, Di Credico A, Guido F, Larici AR, Bonomo L. Incidental detection of pulmonary emboli on routine MDCT of the chest. Am J Roentgenol 2005;184:264-7.